An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients

Author： Wijermans P.   Lübbert M.   Verhoef G.   Klimek V.   Bosly A.  

Publisher： Springer Publishing Company

ISSN： 0939-5555

Source： Annals of Hematology, Vol.84, Iss.1, 2005-12, pp. : 9-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia

By Schaefer Hans   Lübbert Michael  

Annals of Hematology, Vol. 84, Iss. 13, 2005-12 ,pp. : 67-79

Springer Publishing Company

Access to resources Recommend Favorite

The hematopathological basis for studying effects of the demethylating agent 5-aza-2′-deoxycytidine (decitabine) in myelodysplasia

By Schaefer Hans   Lübbert Michael  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 67-79

Springer Publishing Company

Access to resources Recommend Favorite

Epigenetic therapy in MDS and acute AML: focus on decitabine

By Lübbert M.   Wijermans P.  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 1-2

Springer Publishing Company

Access to resources Recommend Favorite

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses

By Giagounidis Aristoteles   Haase Sabine   Heinsch Michael   Göhring Gudrun   Schlegelberger Brigitte   Aul Carlo  

Annals of Hematology, Vol. 86, Iss. 2, 2007-02 ,pp. : 133-137

Springer Publishing Company

Access to resources Recommend Favorite

Clinical experience with decitabine in North American patients with myelodysplastic syndrome

By Yee Karen   Jabbour Elias   Kantarjian Hagop   Giles Francis  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 18-24

Springer Publishing Company

Access to resources Recommend Favorite